← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Cetrorelix

FDA approved · Rx

GnRH receptor antagonist

Also known as: Cetrotide, Cetrorelix Acetate, Cetrorelixum, SB-75, Cetrorelix (INN), SB 75

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 140 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Cetrorelix is a synthetic decapeptide that blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. By blocking these receptors, it rapidly lowers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is sold under the brand name Cetrotide.

What the evidence shows

Automatic summaryHuman trials

Cetrorelix is FDA approved for preventing premature LH surges in women undergoing controlled ovarian stimulation as part of fertility treatment. It has a substantial research record, with about 140 registered human trials reaching Phase 4 and over 600 published papers, while uses outside its approved indication are less established.

Key facts

Molecular formula
C70H92ClN17O14
Molecular weight
1431 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

140registered studies
Phase 4most advanced phase
56completed (sample)
2recruiting (sample)

Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF

RecruitingNCT06023602

Synchronization of Follicle Wave Emergence and Ovarian Stimulation

Phase 4CompletedNCT00439829

Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation

Phase 4CompletedNCT00633347

Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

CompletedNCT04108039

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

663papers referencing Cetrorelix

Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics.

Hum Reprod Update2018

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.

Hum Reprod2000

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.

Hum Reprod1994

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

Fertil Steril2000

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.